Thoma Bravo Announces Strategic Growth Investment In Bluesight To Support The Company'S Acquisition Of Medacist
Thoma Bravo Announces Strategic Growth Investment In Bluesight To Support The Company'S Acquisition Of Medacist
07/17/23, 1:02 PM
Industry
financial services
machine learning
artificial intelligence
biotechnology
health care
analytics
Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication IntelligenceTM Company. The investment is expected to further enhance Bluesight's drug diversion prevention offerings through its acquisition of Medacist, a pioneer in drug diversion monitoring, and continue to grow Bluesight's inventory management and spend optimization offerings. Current investor New Leaf Ventures will remain invested in the business. Financial terms of the transaction were not disclosed.
Company Info
Company info
Thoma Bravo is one of the largest private equity firms in the world, with more than $83 billion in assets under management as of June 30, 2021. The firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging the firm’s deep sector expertise and proven strategic and operational capabilities, Thoma Bravo collaborates with its portfolio companies to implement operating best practices, drive growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings. Over the past 20 years, the firm has acquired more than 325 companies representing over $100 billion in enterprise value. The firm has offices in Chicago, Miami and San Francisco. For more information, visit thomabravo.com.
Unlock Strategic Intelligence with Fundz
This is just a small preview. Unlock the full dataset of company insights, strategic events, and leadership shifts — all in one platform.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.
Trends
| Raised | Growth The data in the raised column shows reported funding for this location/industry over last 90 days. The data in the growth column indicates the % increase or decrease of the last 90 days vs. the previous 90 days. Please note: one or more large fundings, especially for a location/industry that doesn't historically receive much funding, can have a significant impact on the increase or decrease percentage. | |
|---|---|---|
biotechnology | $9.4 B | -20.4% |
health care | $8.6 B | -26.7% |
artificial intelligence | $7.4 B | -66.5% |
machine learning | $4.5 B | -47.4% |
analytics | $831.8 M | 44.4% |